Page 9 - Oncology_11_2021
P. 9

Accord Oncology Portfolio
























































                                                                               THE MOST EXPERIENCED BORTEZOMIB
                                                                               GENERIC IN SOUTH AFRICA 1










                                    AZACITIDINE                                   1 mg & 3,5 mg















             QUALITY ONCOLOGY PRODUCTS MADE ACCESSIBLE AND AFFORDABLE TO MORE SOUTH AFRICANS


       Reference: 1. Oncodata March 2021.
       S4 VALTIB 1 mg (powder for solution for injection). Each vial contains 1,0 mg bortezomib. Reg. No.: 52/26/1027. S4 VALTIB 3,5 mg (powder for solution for injection). Each vial contains 3,5 mg bortezomib.
       The reconstituted solution for intravenous injection contains 1,0 mg/ml bortezomib. Reg. No.: 49/26/0891.  S4 PEMETREXED ACCORD 100 mg (lyophilised powder for solution for infusion). Each 4 ml
       vial contains pemetrexed disodium hemipentahydrate equivalent to 100 mg pemetrexed. Reg. No. 52/26/1002. S4 PEMETREXED ACCORD 500 (lyophilised powder for solution for infusion). Each 20 ml
       vial contains pemetrexed disodium hemipentahydrate equivalent to 500 mg pemetrexed. Reg. No. 49/26/0888.  S4 GRASTIVA 300 mg (pre-filled syringe). Each 0,5 ml pre-filled syringe contains 300 μg
       filgrastim. Reg. No: 48/30.4/1114. S4 GRASTIVA 480 mg (pre-filled syringe). Each 0,5 ml pre-filled syringe contains 480 μg filgrastim. Reg. No: 48/30.4/1115. S4 INTAZA 100 mg (lyophilised powder for
       suspension for injection). Each vial contains 100 mg azacitidine. Reg. No.: 51/26/0453.452. For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority.
       ACCORD HEALTHCARE SA. Building 2, Tuscany Office Park, 6 Coombe Place, Rivonia, Johannesburg, South Africa. Tel: +27 11 234 5701/2/3. www.accord-healthcare.co.za. ACC/015/SEP21/AD




                                                                                                             2021/09/20   10:23
   QUO645 Accord-NEJM-A4Advert v3 FA.indd   1                                                                2021/09/20   10:23
   QUO645 Accord-NEJM-A4Advert v3 FA.indd   1
   4   5   6   7   8   9   10   11   12   13   14